Litcius/Paper detail

Novel Lawsone–Quinoxaline Hybrids as New Dual Binding Site Acetylcholinesterase Inhibitors

Paptawan Suwanhom, Teerapat Nualnoi, Pasarat Khongkow, Varomyalin Tipmanee, Luelak Lomlim

2023ACS Omega11 citationsDOIOpen Access PDF

Abstract

High Resolution Image Download MS PowerPoint Slide A new family of lawsone–quinoxaline hybrids was designed, synthesized, and evaluated as dual binding site cholinesterase inhibitors (ChEIs). In vitro tests revealed that compound 6d was the most potent AChEI (IC 50 = 20 nM) and BChEI (IC 50 = 220 nM). The compound 6d did not show cytotoxicity against the SH-SY5Y neuronal cells (GI 50 > 100 μM). In silico and enzyme kinetic experiments demonstrated that compound 6d bound to both the catalytic anionic site and the peripheral anionic site of Hu AChE. The lawsone–quinoxaline hybrids exhibited potential for further development of potent acetylcholinesterase inhibitors for the treatment of Alzheimer’s disease.

Topics & Concepts

LawsoneQuinoxalineAcetylcholinesteraseChemistryActive siteBinding siteIn silicoEnzymeIC50Docking (animal)BiochemistryCholinesteraseCytotoxicityStereochemistryIn vitroPharmacologyBiologyOrganic chemistryMedicineNursingGeneCholinesterase and Neurodegenerative DiseasesComputational Drug Discovery MethodsSynthesis and Biological Evaluation
Novel Lawsone–Quinoxaline Hybrids as New Dual Binding Site Acetylcholinesterase Inhibitors | Litcius